Immunotherapy formula for the body's ability to produce its own antibodies to prevent the binding of interleukin-2 to the receptor. Use in the treatment of cancer
LAP19AInactive Publication Date: 2018-12-31CENT DE INMUNOLOGIA MOLECULAR CENT DE INMUNOLO
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- LAP19
- Authority / Receiving Office
- LA · LA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2004-11-16
- Filing Date
- 2006-02-06
- Publication Date
- 2018-12-31
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 00000000_0002_ABST 
Figure 00000000_0000_ABST 
Figure 00000000_0001_ABST
Abstract
The present invention relates to a vaccine base and a monoclonal antibody that neutralizes interleukin-2, which is useful in the treatment of various tumors. In particular, the present invention relates to a therapeutic regimen that can enhance the immunogenicity of IL-2 conjugated to the P64K protein carrier from Neisseria meningitides in the montanide ISA 51 adjuvant to generate IL-2 neutralizing autoantibodies and is useful for the treatment of tumors such as breast cancer. Furthermore, the present invention relates to a combination therapy of an IL-2-based vaccine with other cancer vaccines based on tumor-specific antigens or tumor growth factors, as well as standard chemotherapy or radiation therapy used in the treatment of standard cancer diseases.
Need to check novelty before this filing date? Find Prior Art
